Compare Sana Biotechnology Inc (SANA) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Stitch Fix Inc — how do they compare? Sana Biotechnology Inc trades at $3.2 (market cap $873.84M), while Stitch Fix Inc trades at $3.83 (market cap $520.36M). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and Stitch Fix Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SFIX | |
|---|---|---|
Market Cap | $873.84M | $520.36M |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $5.83 |
52-Week Low | $2.68 | $3.06 |
Enterprise Value | $848.03M | $408.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Stitch Fix (SFIX) trades at $3.935, up 3.83% on the day, showing signs of a potential turnaround with recent earnings beats and a bullish technical signal. The company reported a narrowed net loss in 2025, with revenue stabilizing at $1.27 billion and a gross margin of 43.66%. Analyst consensus is a $4.75 price target, though the stock remains near historic lows, presenting a value opportunity amid improving client metrics and AI-driven personalization efforts.
The outlook for SFIX hinges on sustained execution of its turnaround strategy, with risks including consumer spending pressure and competitive threats. Upside potential exists if margin improvements and active client growth continue, but investors should weigh the company's history of net losses against recent positive momentum and analyst caution, with 63.64% holding a neutral stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
